Market Movers: Kiniksa (KNSA) Gains 5.64% to Close at $10.68 June 23

Equities Staff  |

Kiniksa Pharmaceuticals Ltd - Class A (NASDAQ:KNSA) shares gained 5.64% today on 503,988 shares - in comparison to their 30 day average of 295,201 shares traded.

With today’s closing at $10.68 the company has a 50 day moving average of $8.38.

The company anticipates its next earnings on 2022-08-02.

Kiniksa is down 14.10% so far this year.

For technical charts, analysis, and more on Kiniksa visit the company profile.

About Kiniksa Pharmaceuticals Ltd - Class A

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's portfolio of assets, ARCALYST, mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases.

To get more information on Kiniksa Pharmaceuticals Ltd - Class A and to follow the company's latest updates, you can visit the company's profile page here: Kiniksa Pharmaceuticals Ltd - Class A's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content